-+ 0.00%
-+ 0.00%
-+ 0.00%

Atossa Therapeutics FY2025 R&D expense rises to $21 million; (Z)-endoxifen gains FDA orphan drug designation for Duchenne muscular dystrophy

Reuters·03/25/2026 21:30:41

Please log in to view news